JonesResearch says Capricor Therapeutics (CAPR) reported FDA alignment on the HOPE-3 study in Duchenne muscular dystrophy, with topline pivotal data expected in mid-Q4. The FDA did not agree to Capricor’s proposed protocol amendment, but confirmed that HOPE-3 can serve as the “additional study” requested in the complete response letter, meaning Capricor will not have to submit a new application, the analyst tells investors in a research note. Jones believes this puts potential approval on track for mid-2026, ahead of the September 30, 2026 deadline to receive a priority review voucher. It has a Buy rating on the shares with a $29 price target The stock in early trading is up 17% to $7.25.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAPR:
- Unusually active option classes on open September 25th
- Capricor to submit HOPE-3 data with complete response to FDA CRL
- Capricor Therapeutics: Positive Outlook Amid FDA Discussions and Efficacy Demonstrations in DMD Treatment
- Optimistic Buy Rating for Capricor Therapeutics Amid Regulatory and Clinical Advancements
- Closing Bell Movers: Opendoor up 36% after management reshuffle